Gabrielle de Massol

Enabling The Agentic GBS – where AI Agents execute end-to-end business processes, and people focus on decisions and outcomes. Our AI Agents handle P2P, O2C, H2R, and R2R with 90%+ straight-through processing and 20x productivity gains. Trusted by enterprises across Europe and North America.

Doccla is redefining where and how healthcare is delivered. We enable hospitals and health systems to care for patients at home through virtual wards and remote monitoring. Our platform supports patients across the full care journey: from early discharge and acute recovery to long-term condition management and proactive care. Doccla provides everything clinicians need to deliver safe, effective virtual care. That includes medical-grade devices, logistics, patient onboarding, EHR integration and an end-to-end clinical platform designed around real-world workflows. We work with leading health systems including over 60% of NHS ICBs to reduce hospital pressure, improve outcomes, and create a more resilient model of care. Want to learn more or partner with us? 📩 hello@doccla.com 🌐 www.doccla.com 🚀 Interested in joining our team? Check out our careers page.

At Inato, our mission is to bring clinical trials to each and every patient, regardless of who they are or where they live. Today, with 5% of sites running 70% of clinical trials, only patients with privileged access to these sites have an opportunity to participate in trials. We envision a world where it’s so easy to find and apply for the right trials that the other 95% of sites – often community-based research sites – can play a bigger role and accelerate research. By expanding access, we can make clinical trials more accessible, efficient, and inclusive. That’s why we’ve created a platform that connects global pharmaceutical companies with a broader range of research sites, while ensuring reliable high performance. Our exclusive site profiles, trial application & verification processes, and ongoing support help sites get selected and meet enrollment targets, while giving sponsors access to previously untapped patient populations. We’re seeing growing trust in community sites, faster timelines for sponsors and sites, increased patient accessibility, and diversified participation for more inclusive trials. Drug development is a challenging, intellectually complex, and rewarding endeavor. By working together to bring trial access into communities across the globe, we can more efficiently develop treatments that are safe and effective for everyone.

Real-World Data you can trust, at scale. EHR-derived insights from a federated hospital network. High-quality, validated, cNLP-enriched medical data, supported by a secure European infrastructure.

At Tilak, our vision is to transform the way we monitor chronic eye conditions. Our mission is to empower patients with fun and easy-to-use apps that help them (and their doctors’!) better manage their diseases. Founded in 2016 by Pr. José-Alain Sahel (opthalmologist) and Edouard Gasser (ex-Gameloft), Tilaks DNA combines medical expertise with gaming mastery. “You Play, We Care.” Our product is OdySight, the worlds first medical mobile app for vision monitoring supported by a national healthcare system. Since its launch on the French market in 2018, OdySight has been prescribed to 15 000 patients, most of which in France. OdySight is a CE marked medical device available in 5 languages and available on app stores in France, Spain, Belgium and the US.

inHEART is committed to delivering the world’s most sophisticated, AI-enabled, digital twin of the heart to advance the care of patients living with cardiac disease. We believe all patients deserve access to world-class expertise that guides and optimizes treatment strategies to support improved clinical outcomes and return patients to full, healthy lives.

Enabling The Agentic GBS – where AI Agents execute end-to-end business processes, and people focus on decisions and outcomes. Our AI Agents handle P2P, O2C, H2R, and R2R with 90%+ straight-through processing and 20x productivity gains. Trusted by enterprises across Europe and North America.

Doccla is redefining where and how healthcare is delivered. We enable hospitals and health systems to care for patients at home through virtual wards and remote monitoring. Our platform supports patients across the full care journey: from early discharge and acute recovery to long-term condition management and proactive care. Doccla provides everything clinicians need to deliver safe, effective virtual care. That includes medical-grade devices, logistics, patient onboarding, EHR integration and an end-to-end clinical platform designed around real-world workflows. We work with leading health systems including over 60% of NHS ICBs to reduce hospital pressure, improve outcomes, and create a more resilient model of care. Want to learn more or partner with us? 📩 hello@doccla.com 🌐 www.doccla.com 🚀 Interested in joining our team? Check out our careers page.

At Inato, our mission is to bring clinical trials to each and every patient, regardless of who they are or where they live. Today, with 5% of sites running 70% of clinical trials, only patients with privileged access to these sites have an opportunity to participate in trials. We envision a world where it’s so easy to find and apply for the right trials that the other 95% of sites – often community-based research sites – can play a bigger role and accelerate research. By expanding access, we can make clinical trials more accessible, efficient, and inclusive. That’s why we’ve created a platform that connects global pharmaceutical companies with a broader range of research sites, while ensuring reliable high performance. Our exclusive site profiles, trial application & verification processes, and ongoing support help sites get selected and meet enrollment targets, while giving sponsors access to previously untapped patient populations. We’re seeing growing trust in community sites, faster timelines for sponsors and sites, increased patient accessibility, and diversified participation for more inclusive trials. Drug development is a challenging, intellectually complex, and rewarding endeavor. By working together to bring trial access into communities across the globe, we can more efficiently develop treatments that are safe and effective for everyone.

Real-World Data you can trust, at scale. EHR-derived insights from a federated hospital network. High-quality, validated, cNLP-enriched medical data, supported by a secure European infrastructure.

At Tilak, our vision is to transform the way we monitor chronic eye conditions. Our mission is to empower patients with fun and easy-to-use apps that help them (and their doctors’!) better manage their diseases. Founded in 2016 by Pr. José-Alain Sahel (opthalmologist) and Edouard Gasser (ex-Gameloft), Tilaks DNA combines medical expertise with gaming mastery. “You Play, We Care.” Our product is OdySight, the worlds first medical mobile app for vision monitoring supported by a national healthcare system. Since its launch on the French market in 2018, OdySight has been prescribed to 15 000 patients, most of which in France. OdySight is a CE marked medical device available in 5 languages and available on app stores in France, Spain, Belgium and the US.